The biotech company Immunos Therapeutics from Schlieren, Germany, which is researching a next-generation cancer drug, has secured $15.27 million (CHF15 million) in a financing round. At first glance, that may appear to be a modest amount in the international health care environment, but the circumstances surrounding the financing are very interesting.
Born2Invest is a digital media website covering the biotech industry, among others. Our companion app allows you to get your daily dose of financial news from industries like banking, cannabis, innovation in biotechnology.
The financing vehicle of a potential strategic partner
One particular aspect of the fundraising process is that Pfizer Ventures, the financing vehicle of a potential strategic partner, is already participating in this first stage of venture financing (Series A Financing). In addition to Pfizer, the Swiss venture capital firm Biomed Partners acts as co-leader of the financing. Other investors include Redalpine, Schroder Adveq, Wille Finance, and Bernina Bioinvest.
“We at Biomed Partners have successfully invested in several early cancer companies over the past seventeen years, including Glycart Biotechnology from Schlieremer, Germany,” said Markus Hosang of Biomed. Immunos and its new approach have particularly appealed to the company, as the treatment has the potential to help patients, alone or in combination with existing cancer drugs, that do not benefit from long-term current therapies.
Daniel Vasella as independent consultant
Markus Hosang of Biomed Partners and Michael Baran of Pfizer joined the Board of Directors of Immunos. Reinhard Ambros, former Managing Director of the Novartis Venture Fund, and Daniel Vasella, former CEO and Chairman of the Board of Directors of Novartis, will join as independent industry consultants.
In mid-October, Vasella announced his appointment to the board of directors of Numab, a biotech company based in Wädenswil, Germany. The former pharmaceutical manager appears to be ending the “dormancy period” following his commitment to Novartis.
Immunos is a spin-off of the Universities of Zurich and Basel. The company focuses on cancer therapies that target the innate immune system, the nonspecific or innate immune defense. The latest approved cancer therapies are aimed at checkpoint inhibitors that are designed to restart the immobilized immune system. The new funds will be used to finance the Phase I clinical trial of the application.
The novel drug is to be used in the future both as a combined application with checkpoint inhibitors and alone.
The biotech cluster prospers
This financing round brings the up-and-coming biotech cluster Schlieren back into focus. The Bio-Technopark is home to 45 biotech, MedTech and diagnostics companies. The best-known Schlieremer companies include Glycart, which was acquired by Roche in 2005 for $239.38 million (CHF235 million), Molecular Partners, which has been listed on the SIX since 2014, and Kuros, which was created in 2015 through a reverse merger with Cytos Biotechnology.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Neue Burcher Zeitung, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Do Buy/Sell Ads Work on Equity Crowdfunding Portals? The Experience of CrowdFundMe
The bulletin board facilitates the liquidity of financial products placed by CrowdFundMe, allowing the meeting between the supply and demand...
Bitcoin’s Price Crash to Below $30,000 – Altcoins Lose More
Just a few days ago, Robert Kiyosaki had announced a Bitcoin's price crash to $24,000. However, he said that this...
Industrial Cannabis Production to be Promoted in Santa Fe
Last week, a bill was introduced in the Argentinian Chamber of Deputies that promotes the production of hemp and non-psychoactive...
Beekeeping Sector in Burkina: Two Hundred Beekeepers Receive Subsidized Production Kits
A total of 200 beekeepers from the 13 regions will benefit from these beekeeping kits subsidized by the European Union....
IgG Antibodies to SARS-CoV-2 Acquired after Natural Infection are Maintained Beyond 12 Months
A seropersistence study shows that IgG antibodies generated after natural infection are maintained beyond 12 months. This study reveals that...
Business7 days ago
Junior Miner Rockridge Resources Untouched By China Copper Price War as Green Energy Transition Heats Up
Biotech7 days ago
Roche is Awarded the Distribution of Reagents in Soria for Two Million Euros
Crowdfunding7 days ago
AZ Eltif ALICrowd Co Invests One Million in the Startup Fessura through Mamacrowd
Africa7 days ago
Agricultural Aggregation: New Procedures for Granting Subsidies in Morocco